Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

basal insulin

- PMLiVE

Novo Nordisk and Dewpoint partner on insulin resistance drug candidates

Insulin resistance affects around 15.5% to 46.5% of the world’s population

- PMLiVE

Novo Nordisk suspended from ABPI over ‘serious’ code of practice breaches

This is only the eighth time in the past 40 years that ABPI has issued such a significant sanction

- PMLiVE

Novo Nordisk to cut US insulin prices by up to 75% in January 2024

The decision comes just weeks after Eli Lilly announced a similar series of price cuts

- PMLiVE

Eli Lilly/Boehringer’s Jardiance for children with type 2 diabetes accepted by FDA

The incidence of type 2 diabetes in children has nearly doubled over the past two decades

- PMLiVE

Novo Nordisk’s weight-loss drug recommended by NICE

The drug, semaglutide, will be offered to eligible adults for a maximum of two years

- PMLiVE

Novo Nordisk’s type 2 diabetes drug approved by FDA as first-line option

Rybelsus was initially approved in 2019 as a second-line treatment

- PMLiVE

California sues largest US insulin manufacturers and PBMs for overpricing

Eli Lilly, Novo Nordisk and Sanofi produce over 90% of the global insulin supply

- PMLiVE

Oramed’s oral insulin candidate fails to meet phase 3 targets

The company said it expects to end its oral insulin clinical activities for type 2 diabetes

- PMLiVE

Novo Nordisk completes acquisition of Forma Therapeutics in deal worth $1.1bn

The acquisition includes a pipeline of haemoglobinopathies including etavopivat

- PMLiVE

Novo Nordisk’s insulin icodec shows promise as once-weekly type 2 diabetes treatment

Currently, the basal insulin products with the longest duration are injected once daily

- PMLiVE

Novo Nordisk to acquire Forma Therapeutics in deal worth $1.1bn

The acquisition will focus on expanding the company’s blood disorders portfolio

- PMLiVE

Novo Nordisk announces positive phase 2 trial results for type 2 diabetes treatment

More than 4.9 million people in the UK have diabetes, around 90% of which have type 2 diabetes

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links